Clinical Trial Update: Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating single-agent capecitabine as metronomic chemotherapy for head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING